Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Applied DNA Sciences Inc APDN

Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic... see more

NDAQ:APDN - Post Discussion

Applied DNA Sciences Inc > One of the Worst Stocks Ever!
View:
Post by turner20001 on Mar 07, 2024 6:23pm

One of the Worst Stocks Ever!

STRONG SELL RECOMMENDATION - 600 Reasons to Sell this Dumpster Stock
401. In 2022, CEO Hayward made a total of $2,068,000 in compensation.
402. $450,000 was received as salary.
403. $800,000 was received as a Performance Bonus.
404. APDN lost money in 2022. So why does Hayward get a Performance Bonus?
 
405. $800,000 was received in stock options.
406. $18,000 came from other types of compensation.
407. This information comes from proxy statements filed for the 2022 fiscal year.
408. Itemized Lobbying Expenses for Applied DNA Sciences.
409. Sorini, Samet & Associates were paid $120,000 by APDN in 2022.
410. Good companies to invest in are ones that grow revenues and continually increase their free cash flow. But year after year, APDN can’t seem to get its act in order.
 
STRONG SELL RECOMMENDATION - 600 Reasons to Sell this Dumpster Stock
411. On September 17, 2013, Hot Penny Stocks issued this report on APDN.
412. “Applied DNA Sciences Inc. Is In Trouble.” Over 10 years later, nothing has changed!
413. “We last wrote about Applied DNA Sciences …a month and a half ago and back then, the ticker had already taken on a slow and steady course towards the bottom of the charts.”
414. “Since then, the price has dropped from around $0.15 to the 52-week low of $0.11.”
415. “If you think that this sort of performance is not that horrific, then you should probably keep in mind that back in May, no more than four months ago, the ticker was challenging the $0.27 per share mark.”
416. “If you compare the [recent] figures …with the ones found in the financial statement for the first quarter of 2013, you’ll see that in just three months, APDN have managed to eat through more than half of their cash reserves while increasing the current liabilities by almost 90%.”
417. “We’re pretty certain that the deterioration of the company’s financial state played a big part in the descent.”
418. “In the meantime, the stock performance remains as unpredictable as ever.”
419. “Lots of investors are drawn in, lured by the affordable share price and the clever piece of technology.”
420. “But just as many are being scared away by the rather substantial dilution that the shareholders have gone through over the last couple of years.”
 
STRONG SELL RECOMMENDATION - 600 Reasons to Sell this Dumpster Stock
 
421. GPM Law Firm Commences Investigation on Behalf of Applied DNA Sciences Investors.
422. On November 3, 2015, the aforementioned law firm began investigating potential claims on behalf of investors of Applied DNA Sciences Inc. concerning APDN and its officers of possible violations of federal securities laws.
 
423. “On October 29, 2015, Seeking Alpha published a report alleging that the Company “has spent 6.6x more on insider compensation than R&D” and “is now facing imminent insolvency.”
424. “The report also accuses the Company of engaging in fraudulent accounting practices involving a “Valeant-esque” relationship with a “questionably opaque” UK company called Patronus Systems Ltd.”
 
425. “On this news, Applied DNA Sciences shares fell $3.83, or more than 54%, to close at $3.20 on October 29, 2015, thereby injuring investors.”
426. Risk 1: “We have received written notice from Nasdaq that we are not in compliance with Nasdaq's minimum bid price requirements.”
 
427. “We may “require effecting a reverse stock split of our common stock.” Note: the word “may” should be replaced with the word “will.”
428. “We could be delisted from The Nasdaq Stock Market.”
 
429. This “would negatively impact our business, our ability to raise capital, and the market price and liquidity of our common stock.”
430. Risk 2: “We may require additional financing.” Note: the word “may” should be replaced with the word “will.”
 
STRONG SELL RECOMMENDATION - 600 Reasons to Sell this Dumpster Stock
431. We “may in turn require the issuance of additional shares of common stock, preferred stock or other debt or equity securities (including convertible securities).” Note: the word “may” should be replaced with the word “will.”
432. This “would dilute the ownership held by our stockholders.” Thanks Hayward!
433. Risk 3: “We may have conflicts of interest with our affiliates and related parties.” Note: the word “may” should be replaced with the word “will.”
434. “In the past we have engaged in transactions and entered into agreements with affiliates that were not negotiated at arms' length.” Why?
435. Risk 4: “There are a large number of shares of common stock underlying our outstanding options and warrants.”
436. “The sale of these shares may depress the market price of our common stock and cause immediate and substantial dilution to our existing stockholders.” Note: the word “may” should be replaced with the word “will.”
437. Risk 5: “We may be required to repurchase certain of our warrants.” Note: the word “may” should be replaced with the word “will.”
438. Risk 6: Accounting & Financial Operations make up nearly 7% of APDN’s risk.
439. Risk 7: Debt & Financing make up nearly 5% of APDN’s risk.
440. Risk 8: Corporate Activity and Growth make up nearly 10% of APDN’s risk.
 
STRONG SELL RECOMMENDATION - 600 Reasons to Sell this Dumpster Stock
441. Risk 9: Ability to Sell make up nearly 20% of APDN’s risk.
442. Risk 10: Production make up nearly 18% of APDN’s risk.
443. Risk 11: Legal & Regulatory make up nearly 14% of APDN’s risk.
 
444. Risk 12: Tech & Innovation make up nearly 11% of APDN’s risk.
445. Macro & Political make up nearly 5% of APDN’s risk.
446. Some factors that have contributed to APDN’s lack of profitability:
 
447. APDN’s focus on developing new technologies has led to high research and development costs.
448. APDN has struggled to scale its production and sales operations.
449. APDN has faced regulatory hurdles in some markets.
450. APDN has been criticized for its business practices.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities